2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline.
By Thomas J. Smith, J. Khatcheressian, G. Lyman, H. Ozer, J. Armitage, L. Balducci, C. Bennett, S. Cantor, J. Crawford, Scott J. Cross and 12 more. Journal of Clinical Oncology, 2006
1,568 citations recorded by the source corpus.
Subfields: Emergency Medicine, Hematology, Oncology
View Paper: https://www.semanticscholar.org/paper/2f45bd2b509482ed19fc136cfb82990bc16a0dd9
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Oncology
Citations in the corpus
- Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. (2016, background): “Authoritative guidelines have been published regarding the appropriate use of colony-stimulating factors in patients with cancer, with the main goal of reducing neutropenic fever [371,372].”
- Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial (2016, neutral): “29,30 Docetaxel signifi cantly prolonged failure-free and overall survival across the trial population with no evidence that the eff ect varied across diff erent groups in the population; in particular, there is no evidence of a diff erence of the eff ect of docetaxel by metastatic status, for either of…”
- Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update. (2015, background): “Table 2 lists factors associated with poor clinical outcomes or complications resulting from febrile neutropenia or infection.(28)”
- Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. (2012, methodology): “Granulocyte colonystimulating factor was used according to American Society of Clinical Oncology guidelines.(22) Dose adjustments for each study treatment component individually and/or cycle delays (up to 2 weeks) were permitted in the event of toxicity.”